Biotech Companies That Are Progressing Rapidly

LAS VEGAS, NV / ACCESSWIRE / April 4, 2016 / When investing in speculative biotechnology stocks one of the most important factors is cash flow. Does the company have enough financing to get through trials? Because if not, it doesn’t matter how fantastic the potential of its treatment or drug may be, if it doesn’t have the financial wherewithal to reach that point.

That’s why Propanc Health Group Corporation’s (PPCH) recent news is so important. Over the past year the company has made tremendous strides investigating its PRP treatment primarily for patients suffering from pancreatic, ovarian and colorectal cancers. The company has also identified several other potential conditions it’s treatment could be useful for. The company has conducted several animal studies and is close to human trials. They’ve made it this far on a $4 million financing received early last year. They just drew the last couple million from the financing recently which should be enough to get them ready for human trials around the end of this year before their next capital raise.

Bringing us back to PPCH‘s recent news. The company announced their Chief Executive Officer, James Nathanielsz, is set to visit to New York City for meetings with institutional investors interested to learn more about the Company’s future plans for growth.

“Prior to the roadshow, we expect to complete our Scientific Advice meeting with the MHRA (Medicines and Healthcare Products Regulatory Agency), where we have put in a lot of work over the past few months to transition our lead product, PRP, into formal preclinical development and early stage patient trials. There are also other activities which we intend to undertake, such as initiating preliminary partnering discussions for PRP, expanding the Company’s R&D programs and a potential up-listing to a national exchange. All of these activities could really help establish future growth and create long term value for our shareholders.”

Sufficient cash reserves helps ensure there are no financial hiccups in PPCH‘s growth. This is a significant plus for investors interested in emerging growth companies, and could cause a new influx of investors. Meaning if you’ve been on the sidelines, now’s the time to act.

Ohr Pharmaceutical, Inc. (OHRP) had a fantastic day in the market and should continue its run after announcing that it has reached an agreement on the Special Protocol Assessment (SPA) with the United States Food and Drug Administration (US FDA) on the design of the Phase III trial for its lead drug candidate, squalamine lactate ophthalmic solution, 0.2% (“Squalamine,” also known as OHR-102). Based on the agreed upon SPA, Ohr has initiated the first of two planned Phase III global clinical studies evaluating the efficacy and safety of Squalamine, given in combination with Lucentis®, for the treatment of neovascular age-related macular degeneration (wet AMD).

Another company that had a massive day in the market Tuesday and should continue to make investors gains is, Galena Biopharma, Inc. (GALE) who announced that the 70th qualifying disease free survival (DFS) event has been achieved in the NeuVax™ (nelipepimut-S) Phase 3, PRESENT (Prevention of Recurrence in Early-Stage, Node Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) clinical trial. NeuVax is a peptide immunotherapy vaccine currently being evaluated for the prevention of cancer recurrence and is Galena’s lead development agent in multiple ongoing and planned clinical trials.

ContraVir Pharmaceuticals, Inc. (CTRV) was up on heavy trading volume on Tuesday, after the company announced positive results from a study of its hepatitis B virus treatment. The Edison, NJ-based biopharmaceutical company announced the results of a third-party study of the treatment, known as CMX157, which is an anti-Hepatitis B drug. The study found that the treatment compared favorably to a similar treatment, tenofovir alafenamide fumarate (TAF), the company said in a statement.

BioDelivery Sciences International, Inc. (BDSI) has seen a cluster of insider buying in the past two weeks. To start with, Director Charles J. Bramlage purchased 8,850 shares last Monday for $2.82 each, lifting his ownership to 28,150 shares. Chief Technology Officer Niraj Vasisht snapped up 1,000 units of common stock on March 18 at $2.80 apiece, which increased his direct ownership stake to 68,420 shares. Director Barry I. Feinberg bought a 10,000-share block on the same day at a weighted average price of $2.74, which is entirely held by the BIF Family Trust. The Director’s trust fund continues to hold a stake of 15,000 shares. Lastly, Ernest R. De Paolantonio, Chief Financial Officer, Secretary and Treasurer, purchased 4,000 shares a day earlier for $2.60 each, boosting his stake to 13,383 shares. This could be a good sign for the company’s prospects moving forward.

Arrowhead Research Corp. (ARWR) had a huge day Tuesday, and has been quite bullish since the beginning of February, investors may want to keep an eye out for developments on this one.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC. has been compensated $67,000 by Propanc Health Group, Corp. for this news article and for previous as well as future news articles.

Contact:

Acrlasvegas@gmail.com

SOURCE: ACR Communication, LLC

ReleaseID: 438417